Sickle cell anemia treatment does not increase malaria risk in Africa

October 19, 2017, American Society of Hematology

The drug hydroxyurea does not appear to increase the risk of malaria infection in patients with sickle cell anemia who live in malaria-endemic regions, according to a study published online today in Blood, a Journal of the American Society of Hematology (ASH).

Sickle cell anemia (SCA) is an inherited disorder characterized by abnormal red blood cells that stick together in patients' blood vessels, blocking the blood flow to organs, which can lead to severe pain, organ failure, stroke, and even death. In low-resource regions of sub-Saharan Africa, more than 50 percent of with SCA die before the age of five.

Hydroxyurea, a medicine recommended for children with SCA in high-resource settings like the United States and Europe, is not widely prescribed in sub-Saharan Africa, which has the highest burden of SCA in the world. This is partly because of a lack of data that will be effective and safe in low-resource regions. In particular, some research suggests that hydroxyurea could make people with SCA more susceptible to , a serious and sometimes fatal disease spread by mosquitoes and common across sub-Saharan Africa.

"Research has been unclear over whether the changes in immune response caused by hydroxyurea could increase the risk of malaria," said Chandy John, MD, of Indiana University School of Medicine, principal investigator of the trial. "Because hydroxyurea provides such positive outcomes for people in high-resource regions, we want to be sure that this drug is safe for children in low-resource, malaria-prone settings.

To understand if hydroxyurea use is associated with higher rates of malaria in sub-Saharan Africa, researchers from the United States and Uganda established the Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM) trial, a year-long, randomized double-blinded placebo-controlled study.

NOHARM was led on the ground by co-principal investigator Robert O. Opoka, MMED, of Makerere University in Kampala, Uganda. The team recruited 208 children aged 1-4 years and randomly assigned them into one of two treatment arms, in which they received either a fixed dose of hydroxyurea or a placebo for a full year. All patients also received standard bed netting and anti-malaria medication.

"Not only were we pleased to see that the overall incidence of malaria was low, but there was also no correlation between hydroxyurea treatment and the rate or severity of malaria," said co-principal investigator and head of data coordination Russell E. Ware, MD, PhD, of Cincinnati Children's Hospital Medical Center.

The treatment arms did not differ in terms of incidence or severity of or other adverse events. Three children on hydroxyurea experienced a total of five malaria episodes, while seven of those receiving placebo had a total of seven malaria episodes. Two children in the hydroxyurea arm died, one from presumed sepsis and the other from unknown sudden death; one child in the placebo arm died, presumably from sepsis.

Children receiving hydroxyurea also had lower rates of pain crises and hospitalizations. "Because the children prescribed hydroxyurea experienced significantly better outcomes without any increase in malaria risk, we are incredibly encouraged to further explore the drug's use in sub-Saharan Africa," said Dr. Ware.

As overall malaria incidence was low in the NOHARM study population, it will be important to monitor the rate and severity of malaria with hydroxyurea use in areas of higher malaria transmission. Drs. John, Ware, and Opoka are currently in the process of recruiting participants for a follow-up study to gauge the optimal dose for children with SCD in resource-limited, malaria-prone regions.

"It is our hope that these research studies can help establish hydroxyurea as the standard of care for children with sickle cell disease in Africa," said Dr. John.

Explore further: Rapid diagnostic test helps distinguish between severe and uncomplicated malaria in Africa

Related Stories

Rapid diagnostic test helps distinguish between severe and uncomplicated malaria in Africa

August 24, 2017
Malaria is a leading cause of death for children living in Sub-Saharan Africa. Many children in rural areas seek care at local community health clinics, but these clinics lack reliable tests to distinguish severe and uncomplicated ...

Drug treatment means better, less costly care for children with sickle cell disease

September 11, 2013
The benefits of hydroxyurea treatment in people with sickle cell disease are well known—fewer painful episodes, fewer blood transfusions and fewer hospitalizations. Now new research from the Johns Hopkins Children's Center ...

Hydroxyurea improves lung function in children with sickle cell disease

May 18, 2016
For the first time, researchers were able to demonstrate that children diagnosed with sickle cell disease showed improvement in lung function after treatment with hydroxyurea, a treatment that is underused despite its demonstrated ...

Successful outcome prompts early end to sickle cell anemia clinical trial

November 19, 2014
Conclusive data show that hydroxyurea therapy offers safe and effective disease management of sickle cell anemia (SCA) and reduces the risk of stroke, prompting early termination by the National Heart Lung and Blood Institute ...

Pediatric sickle cell study stopped early due to positive results

January 4, 2016
A national sickle cell disease study involving Medical University of South Carolina researchers found that for some children with sickle cell disease, the drug hydroxyurea is as effective as blood transfusions to reduce blood ...

Recommended for you

A new approach to developing a vaccine against vivax malaria

September 21, 2018
A novel study reports an innovative approach for developing a vaccine against Plasmodium vivax, the most prevalent human malaria parasite outside sub-Saharan Africa. The study led by Hernando A. del Portillo and Carmen Fernandez-Becerra, ...

Pre-clinical success for a universal flu vaccine offers hope for third generation approach

September 21, 2018
Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Communications.

Researchers define possible molecular pathway for neurodegeneration in prion diseases

September 21, 2018
A new study has shed light on the mechanisms underlying the progression of prion diseases and identified a potential target for treatment.

Fighting a deadly parasite: Scientists devise a method to store Cryptosporidium, aiding vaccine research efforts

September 21, 2018
In May, just before one of the hottest summers on record, the U.S. Centers for Disease Control and Prevention issued a warning about diseases lurking in recreational water facilities like swimming pools and water playgrounds. ...

Scientists make significant discovery in the fight against drug-resistant tuberculosis

September 20, 2018
A team of scientists have identified a naturally occurring antibiotic that may help in the fight against drug-resistant Tuberculosis.

Anti-cancer drugs may hold key to overcoming antimalarial drug resistance

September 20, 2018
Scientists have found a way to boost the efficacy of the world's most powerful antimalarial drug with the help of chemotherapy medicines, according to new research published in the journal Nature Communications.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.